Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab PK and Safety in Healthy Subjects
NCT02601625Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anifrolumab in systemic lupus erythematosus (SLE) (6 arms), sponsored by AstraZeneca. Primary endpoints: Observed Maximum Serum Concentration up to 85 days, Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration up to 85 days and 6 more. Started Nov 2015; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02601625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601625.